Abstract. Cancer cell-derived immunoglobulin G (cancer-IgG) has been implicated in the pathogenesis and progression of various types of cancer. However, its role in salivary adenoid cystic carcinoma (SACC) remains unclear. The present study aimed to investigate the effects of cancer-IgG on metastasis and prognosis in 96 patients with SACC. Immunohistochemical staining showed that cancer-IgG expression was present in all 96 individual SACC tissues. Additionally, high cancer-IgG expression was significantly correlated with metastasis, nerve invasion and recurrence in SACC (P<0.05). Moreover, cancer-IgG expression was significantly correlated with the survival duration of patients with SACC (P<0.05). Proliferation, cell motility and invasion all decreased significantly following knockdown of cancer-IgG in SACC cells (P<0.05) through population-doubling time, wound healing and transwell invasion assays. Additionally, cancer-IgG-knockdown in SACC cells induced the increased expression of E-cadherin and matrix metalloproteinase 9, and promoted the epithelial-mesenchymal transition, but decreased the expression of F-actin filaments. Taken together, these results showed that the high expression of cancer-IgG was strongly associated with metastasis, recurrence and invasion in SACC, suggesting that cancer-IgG expression could serve as a useful biomarker to predict the prognosis of the disease.
Introduction
Salivary adenoid cystic carcinoma (SACC) is a highly malignant neoplasm, which accounts for ~10% of salivary gland malignancies (1) (2) (3) . In patients with SACC, distant metastasis and perineural invasion are frequently observed, even during early stages of the disease (4) . These features are associated with a poor prognosis and a 5-year survival rate of <41.8% (5) . Several proteins, including the epidermal growth factor receptor, transforming growth factor β-1 and the extracellular matrix (ECM) component fibronectin (6) (7) (8) , have been shown to affect the aggressiveness of SACC. However, the precise mechanisms mediating the aggressive invasiveness of SACC remain unclear. Therefore, novel markers that predict prognosis in patients with SACC require identification and novel treatments must be developed.
According to classical immunology, immunoglobulin (Ig) molecules are only produced by differentiated B-lymphocytes and plasma cells (9) . However, multiple studies have shown that numerous Igs, including IgA, IgM and IgG, can also be produced and secreted by cells of other lineages, including neurons, germ cells and epithelial cells. Notably, non-B cell-derived Igs, particularly IgG, have been found to be overexpressed in a number of types of cancer, including those of the colon, breast, lung, stomach, liver, cervix, ovary, pancreas and prostate gland (10) (11) (12) (13) (14) (15) . Furthermore, cancer cell-derived IgG (cancer-IgG) has been shown to be involved in the progression and survival of cancer cells. Our previous study found that IgG was expressed in epithelial tumor cells in the oral cavity, including in SACC cells (16) , using commercial human IgG antibodies. However, the role of cancer-IgG in the progression of SACC remains unclear. The present study aimed to elucidate the role of cancer-IgG in SACC by using the monoclonal antibody RP215, which specifically recognizes an unidentified glycosylated epitope of the heavy chain of cancer-IgG (RP215-bound IgG) (17) , to investigate the association between cancer-IgG and the clinicopathological characteristics of patients with SACC. Additionally, the effects of cancer-IgG on the proliferation, migration and invasion of SACC cells were examined to provide important insights into the role of cancer-IgG in SACC. Immunohistochemistry (IHC). The RP215 monoclonal antibody was a gift from Professor Gregory Lee (University of British Columbia, Vancouver, BC, Canada). Primary tumor tissues were sectioned into 4-µm thick slices, deparaffinized and rehydrated using a graded ethanol series. Antigen retrieval was conducted by boiling the samples in Tris-EDTA buffer (pH 9.0) for 2 min. All tissues were incubated with the RP215 primary antibody (1:200 dilution) at 4˚C overnight or 37˚C for 1 h. Tissues were then washed thoroughly with PBS, incubated with horseradish peroxidase (HRP)-conjugated goat anti-mouse polyclonal antibodies (1:200, cat. no. ab97022; Abcam, Cambridge, UK) at 37˚C for 20 min. The immunocomplexes were detected using diaminobenzidine (Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd., Beijing, China). The number of positive cells and the intensity of staining were determined in five randomly chosen fields at x200 magnification. The percentage of stained cells per field was graded as follows: 0, Negative; 1, 1-25% of cells; 2, 26-50% of cells; and 3, 51-100% of cells. The staining intensity was graded as follows: 0, Absence of signal; 1, light brown for low-intensity signal; 2, brown for a moderate-intensity signal; and 3, dark brown for a high-intensity signal. The score for each field was obtained by multiplying the frequency grade and the intensity grade; the final score for each section was an average of all five fields. The scores for RP215 staining were described as negative (-) if the field scored 0-1, low expression for a score of 2-3 (+), and high expression for scores of 4-6 and 7-9 (++ and +++, respectively). All evaluations were conducted using a Leica DM4000B/M microscope (Leica Microsystems, Inc., Buffalo Grove, IL, USA).
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Materials and methods
Patient
Western blot analysis. Western blot analysis was performed using standard procedures. Cells were lysed using RIPA buffer with protease inhibitor cocktail (Roche Diagnostics, Basel, Switzerland). Proteins (50 µg) were transferred to nitrocellulose membranes following separation by 12.5% SDS-PAGE, and the membranes were then probed with the following antibodies overnight at 4˚C: RP215 (1 µg/ml), anti-E-cadherin (cat. no. ab184633, dilution 1:1,000) and anti-β-actin (cat. no. ab8226, 1 µg/ml) (both from Abcam). HRP-conjugated secondary antibodies (1:2,000, cat. no. ab97040; Abcam) were used to stain the membranes at room temperature for 1 h. Immunocomplexes were then detected with the eECL Western Blot kit (cat. no. CW00495; Beijing ComWin Biotech Co., Ltd., Beijing, China).
RNA extraction, reverse transcription-polymerase chain reaction (PCR).
Total RNA was isolated from cells using TRIzol Reagent (Thermo Fisher Scientific, Inc.) and then reverse transcribed into cDNA using a SuperScript First-Strand Synthesis system (Thermo Fisher Scientific, Inc.). Quantitative PCR was conducted as previously described (6) . The primers used for gene expression are listed in Table II .
Short interfering RNA (siRNA) synthesis and IgG-knockdown assay. siRNAs (Table III) targeting the constant region of the heavy chain in non-B cell-derived IgG were synthesized by Shanghai GenePharma Co., Ltd. (Shanghai, China). SACC-83 cells were seeded in 6-well culture plates at a density of 1x10 6 cells/well. After 24 h, when the SACC-83 cells had grown to 50-70% confluence, the siRNAs and a non-targeting control (NC) were transfected into the SACC-83 cells using Lipofectamine 2000 (Thermo Fisher Scientific, Inc.) in RPMI-1640 without FBS for 6 h. The medium was then replaced with complete medium without penicillin and streptomycin according to the manufacturer's instructions. The knockdown efficiency was verified by western blot analysis.
Colony formation and population doubling time (PDT)
assays. The number of colony forming units (CFU) and the PDTs were assayed as described in our previous study (6) . In brief, cells were seeded in 100-mm dishes, and aggregates of >50 cells were defined as a CFU after 14 days of incubation. For PDT assays, the cells were seeded in 96-well plates and counted daily.
Wound healing and invasion assays. As described in our previous study (6) , IgG-knockdown and control cells were seeded into 6-well plates, grown to confluence and a scratch was made using a 300-400-µm pipette tip. The average linear speed of movement of the wound edges was quantified over 24 h. Cell invasion assays were performed using Transwell chambers coated with 20 µg ECM gel (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany). After 20 h, the membranes were stained with 1% crystal violet and cells on the upper surface of the membrane were removed using a cotton swab. Cells that had invaded through the membrane were then counted in at least 5 randomized fields under a light microscope. The results were obtained from at least three individual experiments.
Statistical analysis. Correlations between non-B cell-derived
IgG expression and clinicopathological features, including age, sex, local invasion, recurrence and metastasis, were assessed using χ 2 tests (for positive rates) and Mann-Whitney tests (for staining scores). Kaplan-Meier survival curves were used to estimate survival rates in patients with SACC. Comparisons of experimental data were performed to determine differences between knockdown and control SACC cells. Experiments were performed in triplicate. P<0.05 was considered to indicate statistical significance. All analyses were performed using SPSS 19 software (IBM SPSS, Armonk, NY, USA).
Results
Non-B cell-derived IgG expression in SACC.
IgG expression was investigated in SACC samples by immunohistochemical staining with RP215. Positive RP215 signals were primarily detected in the cytoplasm and plasma membrane of the cancer cells, whereas no signal was detected in mesenchymal cells or healthy salivary gland tissue. However, certain cells in the normal glandular ducts exhibited strong staining with RP215 (Fig. 1) .
Next, whether IgG expression was correlated with various clinicopathological parameters in patients with SACC was investigated using IHC. Although there was no significant association between positivity of RP215 staining and sex, age (Table I) , tumor size (data not shown), histological subtype, the level of RP215 staining was significantly associated with metastasis (P=0.019), recurrence (P=0.013) and nerve invasion (P=0.009) (Table I) . Indeed, the rate of metastasis (66.7%), recurrence (70.0%) and nerve invasion (68.6%) was higher in patients with high expression of non-B cell-derived IgG than in those with low expression of IgG (33.3, 30 and 31.4%, respectively). The discrepancy between high and low RP215 staining in SACC tissues is shown in Fig. 2 ; strong positive staining was observed in cases with metastasis, recurrence and nerve invasion.
High cancer-IgG expression is associated with poor overall survival in patients with SACC. With the score for RP215 staining of cancer-IgG expression (T/N) chosen as the cut-off point, the patients were divided into high-and low-expression groups. The patients with high cancer-IgG expression exhibited significantly shorter survival times than those with low cancer-IgG expression (Fig. 3) . The results therefore showed that low cancer-IgG expression in SACC was associated with a poor prognosis. 
Proliferation and motility of cancer cells is suppressed by knockdown of non-B cell-derived IgG.
Two siRNAs that target the constant region of the heavy chain of cancer-IgG were used to knockdown cancer-IgG expression in SACC-83 cells. Consistent with the analysis of clinicopathological characteristics, downregulation of cancer-IgG resulted in reduced cellular motility as evidenced by wound healing assays, in which the healing speed of the IgG-knockdown groups was significantly lower in SACC tissues than in control tissues (Fig. 4A) . Moreover, cancer-IgG-knockdown decreased the invasion of SACC cells (Fig. 4B) . Reduced IgG also suppressed colony formation (Fig. 4C ) and increased PDT (Fig. 4D) . The results of assays analyzing CFUs, PDT, speed and cell numbers after knockdown of IgG in SACC are shown in Table IV .
Knockdown of cancer-IgG suppresses the epithelial-mesenchymal transition (EMT) in SACC cells.
To examine whether cancer-IgG was involved in the EMT, changes in the expression of EMT-associated molecules were evaluated. Knockdown of cancer-IgG significantly enhanced the expression of E-cad herin (Fig. 5A) , which is negatively correlated with the EMT. By contrast, the expression levels of Twist, Slug and ZEB1/2, which are positively correlated with the EMT, were clearly decreased. In addition, IgG-knockdown caused the downregulation of matrix metalloproteinases 2 and 9 (MMP2 and MMP9), whose expression is associated with the invasion and metastasis of cancer cells (although the downregulation of MMP2 was not significant) (Fig. 5B) . Furthermore, transfection with IgG siRNA altered the morphology of the SACC cells, resulting in a polygonal shape and a reduction in membrane ruffles, filopodia, lamellipodia and extensions when compared with control cells, in which F-actin tended to be arranged as filaments and cells exhibited a spindle shape (Fig. 5C ). 
Discussion
In the present study, IgG was found to be highly expressed in SACC tissues; this expression was found to be associated with metastasis, recurrence and nerve invasion in SACC. Additionally, IgG expression was involved in the proliferation, migration and invasion of SACC cell lines in vitro. These results provided important insights into the role of cancer-IgG and could facilitate the identification of biomarkers for SACC and the development of novel therapies for the treatment of the disease.
Studies have demonstrated that IgG is expressed in B cells and non-B cells. Additionally, IgG is overexpressed in various cancer types, including lung, colorectal and breast cancer (11, 13, 19) . In our previous study, the expression of IgG was detected in SACC tissues using commercial antibodies; however, recent studies have suggested that a monoclonal antibody, RP215, which mainly recognizes cancer-IgG, can the P-value between the siRNA1 group and the control; c the P-value between the siRNA2 group and the control. siRNA, short interfering RNA; CFU, colony forming unit; PDT, population doubling time; IgG, immunoglobulin G. be used to discriminate the origin of IgG between B cells and epithelial cancer cells (20, 21) . In the present study, this antibody was used to detect cancer-IgG; it was found that IgG was significantly expressed in primary SACC tissues and an SACC cell line. In addition, adjacent normal salivary gland tissues, particularly gland tubular epithelial cells, also expressed cancer-IgG. However, further studies are required to determine the functions of cancer-IgG expressed by SACC.
In the present study, analysis of tissue from patients with SACC and corresponding clinicopathological characteristics showed that cases without metastasis, recurrence and nerve invasion exhibited a relatively low staining intensity compared with those cases in which metastasis, recurrence and nerve invasion occurred. Moreover, patients with high cancer-IgG expression (indicated by strong RP215 staining) exhibited a marked increase in the rates of metastasis, recurrence and nerve invasion compared with those having low cancer-IgG expression. High cancer-IgG expression was also associated with shorter survival times. Similar results have been reported in patients with lung adenoid carcinoma, further indicating that relatively high cancer-IgG expression may be associated with a poor prognosis (21) . These results suggested that cancer-IgG was positively associated with the progression of SACC and may be a prognostic biomarker for the prediction of outcomes in patients with SACC. On the basis of the immunochemistry results, cancer-IgG may play an important role in the metastasis and invasion of SACC. However, further studies are required to confirm these initial findings.
To date, IgG secreted from cancer cells has been hypothesized to function primarily as an antibody. However, studies have also shown that cancer-IgG has growth factor-like activity and is involved in tumorigenesis, promoting the invasion and survival of cancer cells (20, 21) . In the present study, it was found that SACC cell-derived IgG could promote cell proliferation in SACC-83 cells and that SACC cell-derived IgG significantly promoted cell invasion and migration in SACC-83 cells. Furthermore, cancer-IgG-knockdown suppressed the EMT, as evidenced by the increased expression levels of E-cadherin and decreased levels of Twist, Slug and ZEB1/2, as well as the reduced numbers of lamellipodia and disruption of F-actin filament arrangement. Moreover, MMP9 expression was reduced following cancer-IgG-knockdown, further supporting the fact that the invasive capacity of the tumor cells was impaired. It is possible that cancer-IgG may be associated with the invasion and migration of SACC through induction of the EMT.
In conclusion, the findings of the present study demonstrated that high expression of cancer-IgG was strongly correlated with metastasis, recurrence, nerve invasion and poor prognosis in patients with SACC. In addition, cancer-IgG also promoted cellular motility, aggressiveness and proliferation of SACC cells in vitro. These findings suggest that cancer-IgG can serve as a novel biomarker for predicting the prognosis of SACC and as a potential target for novel cancer therapies. 
